PlA polymorphism of integrin β3 differentially modulates cellular migration on extracellular matrix proteins

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 12, 2002, Pages 1984-1989

  Sajid, Mansoor ^a   Vijayan, K Vinod ^a   Souza, Shiloe ^a   Bray, Paul F ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

3 integrin; Cell migration; PlA polymorphism

Indexed keywords

ALANINE; BETA3 INTEGRIN; CYSTEINE; EPTIFIBATIDE; FIBRINOGEN; FIBRONECTIN; ISOPROTEIN; LEUCINE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PROLINE; PROSTAGLANDIN SYNTHASE; SCLEROPROTEIN; VITRONECTIN; VON WILLEBRAND FACTOR; ALLOANTIGEN; CYCLOOXYGENASE 2; FIBRINOGEN RECEPTOR; ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOPONTIN; SIALOGLYCOPROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL MIGRATION; CHO CELL; COMPLEX FORMATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; GENETIC POLYMORPHISM; NONHUMAN; POLYMORPHIC LOCUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; BIOSYNTHESIS; CELL ADHESION; CELL LINE; CELL MOTION; CHEMISTRY; DIFFUSION CHAMBER; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; GENETICS; HAMSTER; METABOLISM; PHYSIOLOGY;

ANIMALS; CELL ADHESION; CELL LINE; CELL MOVEMENT; CHO CELLS; CRICETINAE; CYCLOOXYGENASE 2; DIFFUSION CHAMBERS, CULTURE; ENZYME ACTIVATION; EXTRACELLULAR MATRIX PROTEINS; FIBRINOGEN; INTEGRIN BETA3; ISOANTIGENS; ISOENZYMES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; OSTEOPONTIN; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POLYMORPHISM, GENETIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN ISOFORMS; SIALOGLYCOPROTEINS; VITRONECTIN; VON WILLEBRAND FACTOR;

EID: 0036882102     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000043664.48689.7F     Document Type: Article

References (31)

1. Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Ani Coll Cardiol. 1996;28:1643-1651.
2. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: The platelet paradigm. Blood. 1998;91:2645-2657.
3. 3 in vascular biology. Thromb Haemost 1998;80:726-734.
4. Kim HO, Jin Y, Kickler TS, Blakemore K, Kwon OH, Bray PF. Gene frequencies of the five major human platelet antigens in African American, white, and Korean populations. Transfusion. 1995;35:863-867.
5. Williams MS, Bray PF. Genetics of arterial prothrombotic risk states. Exp Biol Med (Maywood). 2001:226:409-419.
6. Davies MG, Hagen PO. Pathobiology of intimal hyperplasia. Br J Surg. 1994;81:1254-1269.
7. A polymorphisms display different sensitivities to agonists. Circulation. 2000;101:1013-1018.
8. A polymorphism: The Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 1999;19:1142-1147.
9. A2 polymorphism of integrin β3 enhances outside-in signaling and adhesive functions. J Clin Invest 2000;105:793-802.
10. 3 integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation. 2001:104:2666-2672.
11. Casscells W. Migration of smooth muscle and endothelial cells: Critical events in restenosis. Circulation. 1992;86:723-729.
12. 3-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: Correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation, 2001;103:2501-2507.
13. 3 receptors are not protected from atherosclerosis. Circulation. 2002;105:1044-1048.
14. Bini A. Fenoglio JJ Jr, Mesa-Tejada R, Kudryk B, Kaplan KL. Identification and distribution of fibrinogen fibrin, and fibrin(ogen) degradation products in atherosclerosis: Use of monoclonal antibodies. Arteriosclerosis. 1989;9:109-121.
15. Suh TT, Holmback K, Jensen NJ, Daugherty CC, Small K, Simon DI, Potter S, Degen JL. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 1995;9:2020-2033.
16. Liu C-Y, Sun Q-H, Wang R, Paddock CM, Newman PJ. Disruption of the long-range GPIIIa Cys5-Cys435 disulfide bond results in the production of a constitutively active GPIIb-IIIa integrin complex. Blood. 1997;90:573a.
17. 5-directed cell motility but not adhesion on vitronectin. J Cell Biol. 1994;127:859-866.
18. Huttenlocher A, Ginsberg MH, Horwitz AF. Modulation of cell migration by integrin-mediated cytoskeletal linkages and ligand-binding affinity. J Cell Biol. 1996;134:1551-1562.
19. Stockton RA, Jacobson BS. Modulation of cell-substrate adhesion by arachidonic acid: lipoxygenase regulates cell spreading and ERKI/2-inducible cyclooxygenase regulates cell migration in NIH-3T3 fibroblasts. Mol Biol Cell. 2001;12:1937-1956.
20. 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med. 2001;7:1041-1047.
21. Huttenlocher A, Sandborg RR, Horwitz AF. Adhesion in cell migration. Curr Opin Cell Biol. 1995;7:697-706.
22. 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. J Cell Biol. 1995;130:441-450
23. 3. Thromb Haemost Haeniost. 2001;86:1188a.
24. Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A, Mueller BM. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA. 2001;98:1853-1858.
25. Xie H, Pallero MA, Gupta K, Chang P, Ware MF, Witke W, Kwiatkowski DJ, Lauffenburger DA, Murphy-Ullrich JE, Wells A. EGF receptor regulation of cell motility: EGF induces disassembly of focal adhesions independently of the motility-associated PLCσ signaling pathway. J Cell Sci. 1998;111:615-624.
26. 3 in complex with an Arg-Gly-Asp ligand. Science. 2002;296:151-155.
27. A2 polymorphism and efficacy of aspirin. Lancet. 1998;351:1253.
28. Theodoropoulos I, Christopoulos C, Metcalfe P, Dimitriadou E, Economopoulos P, Loucopoulos D. The effect of human platelet alloantigen polymorphisms on the in vitro responsiveness to adrenaline and collagen. Br J Haematol. 2001;114:387-393.
29. 3 subunit (glycoprotein IIIa). Br J Haematol 2000;110:911-918.
30. Coller BS. Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics. J Clin Invest 1997;100:S57-S60.
31. A2 polymorphism. Am Heart J. 2002;143:76-82.